KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $447.0 million.

  • Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) rose 58.18% to $447.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.0 million, marking a year-over-year increase of 58.18%. This contributed to the annual value of $274.2 million for FY2024, which is 31.92% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $447.0 million for Q3 2025, which was up 7.10% from $417.4 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $447.0 million during Q3 2025, with a 5-year trough of $23.0 million in Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $242.2 million (2024), whereas its average is $283.4 million.
  • Data for Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY soared of 672.46% (in 2021) over the last 5 years.
  • Over the past 5 years, Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $125.3 million in 2021, then surged by 40.04% to $175.5 million in 2022, then increased by 18.41% to $207.9 million in 2023, then skyrocketed by 31.92% to $274.2 million in 2024, then skyrocketed by 58.18% to $447.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $447.0 million for Q3 2025, versus $417.4 million for Q2 2025 and $402.8 million for Q1 2025.